Tag: Phase 3
-
Moderna’s Personalized mRNA Cancer Therapy Delivers First Phase 3 Win
Moderna and Merck’s personalized mRNA cancer therapy intismeran met both recurrence-free survival and distant metastasis-free survival endpoints in Phase 3 melanoma, marking a major milestone for individualized mRNA-based cancer treatment.
-
Amylyx Turns GLP-1 Biology in the Opposite Direction
Avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, reducing Level 2 and Level 3 hypoglycemic events by 55% versus placebo in patients with post-bariatric hypoglycemia.
-
Vyvgart Moves Into Autoimmune Muscle Disease After Phase 3 Win
Vyvgart Hytrulo met the primary endpoint in the Phase 3 ALKIVIA study, strengthening argenx’s case for expanding FcRn inhibition into autoimmune muscle disease.
-
Tarsus Bets Up to $800 Million on a Deuterated Vitamin A Drug
Tarsus is acquiring Alkeus for up to $800 million, gaining gildeuretinol, a Phase 3 deuterated vitamin A therapy for Stargardt disease.
-
Jazz to Withdraw Zepzelca’s Second-Line SCLC Indication After Phase 3 Failure
Jazz plans to withdraw Zepzelca’s second-line small cell lung cancer indication after the Phase 3 LAGOON trial failed to confirm an overall survival benefit.